BHVN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BHVN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-15), Biohaven's share price is $29.15. Biohaven's Book Value per Share for the quarter that ended in Dec. 2024 was $4.18. Hence, Biohaven's PB Ratio of today is 6.97.
The historical rank and industry rank for Biohaven's PB Ratio or its related term are showing as below:
During the past 5 years, Biohaven's highest PB Ratio was 15.00. The lowest was 0.00. And the median was 0.00.
During the past 12 months, Biohaven's average Book Value Per Share Growth Rate was -20.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 62.90% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Biohaven was 124.20% per year. The lowest was 62.90% per year. And the median was 93.55% per year.
The historical data trend for Biohaven's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohaven Annual Data | |||||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||
PB Ratio | - | - | 1.76 | 8.11 | 8.93 |
Biohaven Quarterly Data | ||||||||||||||||
Dec20 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
PB Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
8.11 | 14.84 | 8.35 | 15.01 | 8.93 |
For the Biotechnology subindustry, Biohaven's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Biohaven's PB Ratio distribution charts can be found below:
* The bar in red indicates where Biohaven's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Biohaven's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Dec. 2024) |
= | 29.15 | / | 4.183 | |
= | 6.97 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Biohaven (NYSE:BHVN) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Biohaven's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
John W Childs | director | 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199 |
Vlad Coric | director, officer: Chief Executive Officer | C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
Gregory Bailey | director | 4 A CHESHAM STREET, LONDON X0 SW1X8DT |
Bruce Car | officer: Chief Scientific Officer | AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Irina Antonijevic | director | 215 CHURCH STREET, NEW HAVEN CT 06510 |
Matthew Buten | officer: Chief Financial Officer | 215 CHURCH STREET, NEW HAVEN CT 06510 |
George C. Clark | officer: VP, Chief Accounting Officer | 215 CHURCH STREET, NEW HAVEN CT 06510 |
Julia P Gregory | director | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Robert J Hugin | director | C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054 |
Michael Thomas Heffernan | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Kimberly Gentile | officer: SVP, Clinical Operations | C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
Kishan Mehta | director | 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019 |
Biohaven Pharmaceutical Holding Co Ltd. | 10 percent owner | 215 CHURCH STREET, NEW HAVEN CT 06510 |
From GuruFocus
By GuruFocus Research • 04-25-2024
By PRNewswire • 09-30-2024
By PRNewswire • 04-17-2024
By PRNewswire • 11-25-2024
By PRNewswire • 02-11-2025
By GuruFocus Research • 04-23-2024
By PRNewswire • 01-07-2025
By GuruFocus News • 02-11-2025
By PRNewswire • 11-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.